等温核酸扩增技术的全球市场：市场规模和占有率分析（依产品、技术、应用和最终用户）、产业成长预测（截至2030年）

市场概况

全球等温核酸扩增技术（INAAT）市场2023年营收为44.255亿美元，预计到2030年将达到81.594亿美元，2024年至2030年复合年增长率为9.4%。这一增长的推动因素是分子检测技术的使用大幅增加，因为结核病、肝炎和流感等传染病的盛行率不断上升，这些疾病是导致死亡的主要原因，尤其是在发展中国家。

重要见解

2023年，耗材品类预计将透过引领恆温核酸扩增技术产业保持主导地位，占70%的收入占有率。这些试剂在诊断实验室和主要医疗机构中的广泛使用促成了这一优势。

由于 COVID-19 等传染病的新型诊断技术的研发投资增加，预计设备类别将出现最快的成长。

到2023年，医院类别预计将占INAAT产业60%的占有率，并由于小型化POC设备的使用不断增加而保持其主导地位。

由于患者数量的增加以及早期疾病检测分子技术的采用，以及公共机构用于缓解传染病的资金的支持，诊断中心预计将实现最高的复合年增长率。

到 2023 年，北美将占市场约 45%，由于已建立的研究基础设施和对基于核酸扩增的诊断的需求，预计该市场将出现强劲增长。高昂的人均医疗保健成本和对现场诊断的兴趣正在推动北美市场的扩张。

到2023年，环介导扩增预计将占INAAT产业销售占有率的40%，并继续占据主导地位。升级到 LAMP 技术可在等温条件下实现高度定向、高生产率和快速的原位 DNA 製造流程。

本报告分析了全球等温核酸扩增技术市场，提供了市场的基本结构、最新情况、主要推动和抑制因素以及全球、依地区和主要国家的市场规模前景（价值基础、 2017 -2030），依产品、技术、应用和最终用户划分的详细趋势、市场竞争现状以及主要公司概况。

目录

第一章 调查范围

第二章研究方法

第三章执行摘要

第四章 市场指标

第五章 产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/课题
  • 促进/抑制因素影响分析
• 新型冠状病毒感染（COVID-19）的影响
• 波特五力分析

第六章 世界市场

• 概述
• 市场收入：依产品分类（2017-2030）
• 市场收入：依技术分类（2017-2030）
• 市场收入：依应用分类（2017-2030）
• 市场收入：依最终用户分类（2017-2030）
• 市场收入：依地区（2017-2030）

第七章 北美市场

• 概述
• 市场收入：依产品分类（2017-2030）
• 市场收入：依技术分类（2017-2030）
• 市场收入：依应用分类（2017-2030）
• 市场收入：依最终用户分类（2017-2030）
• 市场收入：依国家分类（2017-2030）

第八章欧洲市场

第九章亚太市场

第十章 拉丁美洲市场

第十一章 中东/非洲市场

第十二章 美国市场

• 概述
• 市场收入：依产品分类（2017-2030）
• 市场收入：依技术分类（2017-2030）
• 市场收入：依应用分类（2017-2030）
• 市场收入：依最终用户分类（2017-2030）

第十三章 加拿大市场

第十四章 德国市场

第十五章 法国市场

第十六章 英国市场

第十七章 义大利市场

第十八章 西班牙市场

第十九章 日本市场

第20章 中国市场

第21章 印度市场

第22章澳洲市场

第23章 韩国市场

第24章 巴西市场

第25章 墨西哥市场

第26章 沙乌地阿拉伯市场

第27章南非市场

第28章 阿拉伯联合大公国（UAE）市场

第29章竞争格局

• 市场参与者及其产品清单
• 主要企业竞争基准
• 主要公司的产品基准
• 近期策略发展

第三十章 公司简介

• Becton, Dickinson and Company
• QIAGEN N.V.
• Quidel Corporation
• bioMerieux SA
• Abbott Laboratories
• Meridian Bioscience Inc.
• Thermo Fisher Scientific Inc.
• Atila Biosystems
• Grifols S.A.
• Eiken Chemical Co. Ltd.

第31章附录

Market Overview

The global isothermal nucleic acid amplification technology market generated revenue of USD 4,425.5 million in 2023 and is expected to witness a CAGR of 9.4% during 2024-2030, reaching USD 8,159.4 million by 2030. This growth is attributed to the significant increase in its usage as a molecular testing technique due to the rising prevalence of infectious diseases, including tuberculosis, hepatitis, and influenza, which are among the leading causes of death, particularly in developing countries.

Tuberculosis, hepatitis, and flu are diseases transmitted by way of infectious diseases in which the leading cause of death is mostly observed in underdeveloped countries.

a bewildering range of diagnostic tests combined with an increasing number of Emergency Use Authorizations for CLIA-waived tests are spurring the development of the isothermal nucleic acid amplification technology market. These tests being free of complex procedures, lesser chances of error, and being able to personalize the dose on patients are a few instances of why these tests remain so popular.

These technologies have various uses such as gene manipulation that is done with recombinant DNA and similar molecular biology practices. It is a new way to detect prepare and analyze a small number of nucleic acids containing DNA or RNA that enter into cells.

Historically, there has never been a life history that was free from infectious diseases and this has continued to be a major cause of death and disability. With the increasing incidences of communicable diseases around the world which as weighty factors in the market expansion, this field is seeing major growth nowadays.

Key Insights

In 2023, the consumables category led the isothermal nucleic acid amplification technology industry, with a 70% revenue share, projected to uphold supremacy.

The wide use of reagents in diagnostic laboratories and major healthcare settings contributes to this supremacy.

Obtainability of polymerases with high strand displacement abilities further boosts demand for consumables.

Companies are making numerous reagents to sense communicable diseases, confronting the growing occurrence.

Increasing cases of cardiovascular illnesses, diabetes, and cholesterol-linked illnesses drive the growth of convenient POC diagnostic devices.

The instruments category is expected to show the fastest growth due to increased R&D investments in novel diagnostic techniques for infectious diseases like COVID-19.

In 2023, the hospital's category led with a 60% share in the INAAT industry, projected to uphold supremacy because of the augmented usage of miniaturized POC instruments.

Increased throughput and automation capabilities of INAAT technologies for processing large sample volumes are expected to drive segment growth.

Diagnostic centers forecast the highest CAGR due to rising numbers and the adoption of molecular techniques for early disease detection, supported by funding from public agencies for infectious disease mitigation.

North America held around 45% of the market in 2023, poised for robust growth due to established research infrastructure and demand for nucleic-acid-amplification-based diagnostics.

High per capita healthcare spending and interest in point-of-care diagnostics drive market expansion in North America.

In 2023, loop-mediated amplification dominated the INAAT industry with a 40% revenue share, projected to uphold supremacy.

LAMP technology upgrades allow highly directive, productive, and fast in-situ DNA manufacturing process under isothermal conditions.

There recruitation of DNA polymerase and four primer adds protrusion of six different motifs on target DNA in DNA replication.

The kit is a microbial identification method which includes three types of detection techniques (lateral flow, agarose gel detection, and real-time fluorescence with intercalators)

LAMP against PCR's resistance to interactive molecules is that samples can be used even in the less purified form.

It has a potential for testing all RNA and DNA sequences at the same time and is capable of detecting both Zika and SARS-CoV-2 viruses in human specimens.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by technology
  • 1.4.3. Market size breakdown, by application
  • 1.4.4. Market size breakdown, by end user
  • 1.4.5. Market size breakdown, by region
  • 1.4.6. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Technology (2017-2030)
• 6.4. Market Revenue, by Application (2017-2030)
• 6.5. Market Revenue, by End User (2017-2030)
• 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Technology (2017-2030)
• 7.4. Market Revenue, by Application (2017-2030)
• 7.5. Market Revenue, by End User (2017-2030)
• 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Technology (2017-2030)
• 8.4. Market Revenue, by Application (2017-2030)
• 8.5. Market Revenue, by End User (2017-2030)
• 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Technology (2017-2030)
• 9.4. Market Revenue, by Application (2017-2030)
• 9.5. Market Revenue, by End User (2017-2030)
• 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Technology (2017-2030)
• 10.4. Market Revenue, by Application (2017-2030)
• 10.5. Market Revenue, by End User (2017-2030)
• 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Technology (2017-2030)
• 11.4. Market Revenue, by Application (2017-2030)
• 11.5. Market Revenue, by End User (2017-2030)
• 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Technology (2017-2030)
• 12.4. Market Revenue, by Application (2017-2030)
• 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Technology (2017-2030)
• 13.4. Market Revenue, by Application (2017-2030)
• 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Technology (2017-2030)
• 14.4. Market Revenue, by Application (2017-2030)
• 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Technology (2017-2030)
• 15.4. Market Revenue, by Application (2017-2030)
• 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Technology (2017-2030)
• 16.4. Market Revenue, by Application (2017-2030)
• 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Technology (2017-2030)
• 17.4. Market Revenue, by Application (2017-2030)
• 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Technology (2017-2030)
• 18.4. Market Revenue, by Application (2017-2030)
• 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Technology (2017-2030)
• 19.4. Market Revenue, by Application (2017-2030)
• 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Technology (2017-2030)
• 20.4. Market Revenue, by Application (2017-2030)
• 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Technology (2017-2030)
• 21.4. Market Revenue, by Application (2017-2030)
• 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Technology (2017-2030)
• 22.4. Market Revenue, by Application (2017-2030)
• 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Technology (2017-2030)
• 23.4. Market Revenue, by Application (2017-2030)
• 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Technology (2017-2030)
• 24.4. Market Revenue, by Application (2017-2030)
• 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Technology (2017-2030)
• 25.4. Market Revenue, by Application (2017-2030)
• 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Technology (2017-2030)
• 26.4. Market Revenue, by Application (2017-2030)
• 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Technology (2017-2030)
• 27.4. Market Revenue, by Application (2017-2030)
• 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Technology (2017-2030)
• 28.4. Market Revenue, by Application (2017-2030)
• 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Becton, Dickinson and Company
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. QIAGEN N.V.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Quidel Corporation
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. bioMerieux SA
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Abbott Laboratories
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Meridian Bioscience Inc.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Thermo Fisher Scientific Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Atila Biosystems
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Grifols S.A.
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Eiken Chemical Co. Ltd.
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports